Business Wire

Innovation in Resistance Management: VECTRONTM T500, a New Vector Control Product, is Prequalified by the World Health Organization (WHO)

Share

VECTRONTM T500 is a new IRS product containing TENEBENALTM, the world’s first meta-diamide active ingredient (IRAC Group 30) developed by Mitsui Chemicals Agro which has a different mode of action from existing vector control products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005328/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mosquitoes in Bugesera district, Rwanda. Photographed by Mitsui Chemicals Agro.

VECTRONTM T500 will support the rotation of insecticides in line with best practice insecticide resistance management, which is critical to preserve the long-term efficacy of vector control tools. VECTRONTM T500 has outstanding efficacy against malaria vector mosquitoes including strains and populations resistant to pyrethroids and some other insecticides. It works on a variety of types of wall surfaces, including mud, and shows long residual efficacy.

VECTRONTM T500 is non-repellent, odorless and stainless formulation with low mammalian acute toxicity, and is supplied in easy-to-handle 50g aluminum sachets.

Mitsui Chemicals Agro will launch VECTRONTM T500 in sub-Saharan African countries from 2023 in line with locally required conditions of use.

OZAWA says: “Mitsui Chemicals Agro is an R&D driven chemical company, that has been developing malaria vector control products to save human lives. Our mission is to provide solutions to health challenges through the development and deployment of innovative, high-quality products. We are committed to malaria eradication and are excited about the launch of VECTRONTM T500. We appreciate the support of all our stakeholders and partners in reaching this important milestone.”

Justin McBeath CEO of IVCC added: “IVCC was established with a mission to work with partners, such as Mitsui Chemicals Agro, to accelerate the availability of new public health insecticides which will help address the significant threat of insecticide resistance in malaria vectors. We are delighted to have supported Mitsui Chemicals Agro on their achievement of the PQ-listing of this important breakthrough product which represents another significant milestone in the fight against malaria.”

Notes to Editors

Mitsui Chemicals Agro, Inc.

Mitsui Chemicals Agro is an R&D driven company that is a global provider of solutions by high-quality products and services in the agrochemicals field. The company has a history of about 100 years beginning with the manufacture and release of the first synthetic agrochemical in Japan. Mitsui Chemicals Agro has been contributing human health and comfortable life through PPM (Professional Pest Management) business, providing unique active ingredients and formulated products. Mitsui Chemicals Agro is 100% subsidiary of Mitsui Chemicals (Tokyo:4183, ISIN: JP3888300005) which has an annual sale of 1,612 billion yen in the fiscal year ending March 2022.

IVCC

IVCC is the only Product Development Partnership (PDP) working in vector control. IVCC was established in 2005, through an initial $50 million grant to the Liverpool School of Tropical Medicine (LSTM) from the Bill & Melinda Gates Foundation and has since provided ongoing support for IVCC activities. As a registered charity in the UK, IVCC is also funded by UK Aid, USAID and the Swiss Agency for Development and Cooperation to work with stakeholders to facilitate the development of novel and improved public health insecticides and formulations to combat the rapidly growing problem of insecticide resistance. In addition, IVCC is also funded by Unitaid and the Global Fund to implement catalytic market access projects, such as NgenIRS and the New Nets Project which support the rapid and scaled deployment of innovative vector control interventions. IVCC brings together partners from industry, the public sector and academia to create new solutions to prevent disease transmission. By focusing resources and targeting practical scientific solutions we accelerate the process from innovation to impact.

Reference

*1) WHO -Prequalification of Vector Control Products- VECTRONTM T500
https://extranet.who.int/pqweb/vector-control-product/vectron-t500

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for inquiries about VECTRONTM T500
International Business Div.
Mitsui Chemicals Agro, Inc.
E-mail: MCAG-Vectron@mitsuichemicals.com

Contacts for inquiries about this project
Corporate Communication Div.
Mitsui Chemicals, Inc.
URL: https://form.mitsuichemicals.com/corporate/cc_pr_csr_en

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

China’s Top Baijiu Brand Moutai Showcases China's Green Progress in Manufacturing at COP3015.11.2025 18:41:00 EET | Press release

On November 10 local time, the 30th United Nations Climate Change Conference (COP30) opened in Belem, a city in northern Brazil. As one of the activities at the China Pavilion of COP30, the Side Event on Ecological Civilization and Beautiful China Practice was held simultaneously, focusing on ecological civilization, sharing China's experience, and building global consensus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114596036/en/ China Pavilion at COP30 in Belem, Brazil. Addressing the topic of green transformation in traditional industries, You Yalin, Deputy Party Secretary of Kweichow Moutai Co., Ltd., shared the company's green transformation practices and experiences from the perspective of a traditional Chinese liquor producer. “We hope that every bottle of Moutai not only delivers a feast of flavor, but also conveys the idea of harmony between humans and nature. We aim to contribute China's wisdom and Moutai's

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release

Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado

Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release

3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye